- Primary menu
- Home
- Publish With Us
- Contributors
- About Us
- Contact Us
- Advertise
- Sign Up For NLR Bulletins
- QUICK LINKS
- Antitrust Law
- |
- Bankruptcy & Restructuring
- |
- Biotech & Cleantech
- |
- Business of Law
- |
- Election
- Construction & Real Estate
- |
- Environmental, Energy & Resources
- |
- Financial, Securities & Banking
- Health Care
- |
- Immigration
- |
- IP Law
- |
- Insurance
- |
- Labor & Employment
- |
- Litigation
- |
- Media & FCC
- |
- Tax
James S. Cohen, Partner
- 202-756-8276
- jcohen@mwe.com
- www.mwe.com
James (Jim) S. Cohen is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm’s Washington, D.C., office. He is head of the Firm's Food and Drug Administration (FDA) practice. Jim focuses his practice on the development, clinical investigation, approval, and marketing of drugs, medical devices, biologics, combination products, and other FDA regulated products. He has been recognized by Legal 500 as one of the leading lawyers in his field.
- McDermott Will & Emery
Articles in the National Law Review database by James S. Cohen:
- Federal Court Vacates Conviction for Truthful Off-Label Promotion of FDA-Approved Drug (Posted On Tue, 2012-12-11 15:16)
- New Flexibility for Pharmaceutical and Medical Device Companies in Massachusetts, but at a Price (Posted On Thu, 2012-08-02 15:08)
- FCC Announces Rulemaking Enabling Remote Monitoring of Health Care Data (Posted On Thu, 2012-06-21 16:05)
- FDA Finalizes Rule Expanding Scope of Clinical Investigator Disqualification (Posted On Tue, 2012-05-22 19:53)
- FDA Finalizes Benefit-Risk Determination Methodology for Certain Medical Devices (Posted On Sun, 2012-04-22 13:38)
- FDA Issues Draft Guidance Implementing Direct-to-Consumer Television Ad Pre-Dissemination Review Program (Posted On Mon, 2012-04-09 15:54)
- IFPMA Releases Revised Code for Interactions with Health Care Professionals and Other Stakeholders (Posted On Tue, 2012-03-20 08:11)
- FDA Schedules Public Hearing to Evaluate Potential New Drug Approval Paradigm (Posted On Wed, 2012-03-07 21:02)
- FDA Publishes Draft Biosimilars Guidance (Posted On Fri, 2012-02-17 14:24)
- FDA Clarifies Use of Product Names in Advertising and Promotional Labeling (Posted On Sat, 2012-02-04 11:27)
- FDA Issues Draft Guidance, Requests Public Comments on Communication of Off-Label Information (Posted On Thu, 2012-01-05 17:00)
- HHS Extends Comment Period for Advanced Notice of Proposed Rule Making Concerning the Common Rule (Posted On Sun, 2011-09-11 03:34)
- The IOM Report on Reform of the 510(k) Device Clearance Process and Beyond (Posted On Fri, 2011-08-19 11:12)
- HHS Proposes Overhaul of Human Subject Protections for Domestic Clinical Trials (Posted On Thu, 2011-07-28 10:48)
Boost: AJAX core statistics
Advertisement
Recent Contributions to the National Law Review
Beveridge & Diamond PC
McDermott Will & Emery
Morgan, Lewis & Bockius LLP
Womble Carlyle Sandridge & Rice, PLLC
Sheppard, Mullin, Richter & Hampton LLP
Schwegman, Lundberg & Woessner, P.A.
Poyner Spruill LLP
von Briesen & Roper, S.C.
Dickinson Wright PLLC
Much Shelist, P.C.
Armstrong Teasdale
Katten Muchin Rosenman LLP
Allen Matkins Leck Gamble Mallory & Natsis LLP
Bracewell & Giuliani LLP
Barnes & Thornburg LLP
Armstrong Teasdale
McDermott Will & Emery






